Head-to-head evidence
AG2304R vs MK0653A, ezetimibe (+) simvastatin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
AG2304R
Developed by Ahn-Gook Pharmaceutical
NCT06717360 · Phase 3 · completed
The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.
MK0653A, ezetimibe (+) simvastatin
Developed by Organon
NCT00092651 · Phase 3 · completed
The study was randomized and double-blind, included active comparator groups, and enrolled 1,398 participants. Its primary endpoint was the surrogate measure of change in plasma LDL-C after 12 weeks, but results and statistical significance were not posted, so the endpoint cannot be judged as met or missed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304R's landscape · MK0653A, ezetimibe (+) simvastatin's landscape